Emtricitabine News and Research

RSS
Emtricitabine, also known as Emtriva or FTC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Emtricitabine in capsule form was approved by the FDA on July 2, 2003, for use with other antiretroviral agents in the treatment of HIV infection in adults. Emtricitabine oral solution was approved by the FDA on September 28, 2005, and is now approved for use with other anti-HIV drugs in the treatment of HIV-1 infection in patients older than 3 months of age. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
FDA approves two-drug complete regimen for previously untreated HIV-infected adults

FDA approves two-drug complete regimen for previously untreated HIV-infected adults

New clinical trial aims to examine safety and use of two HIV prevention tools

New clinical trial aims to examine safety and use of two HIV prevention tools

MTN launches new study to empower teen girls with choices in HIV prevention

MTN launches new study to empower teen girls with choices in HIV prevention

PrEP shown to be safe and effective for widespread use

PrEP shown to be safe and effective for widespread use

NIH launches large study to compare treatments for pregnant women with HIV

NIH launches large study to compare treatments for pregnant women with HIV

New HIV prevention guidelines from Canada released

New HIV prevention guidelines from Canada released

Study: PrEP program for men who have sex with men could lead to long-term cost savings

Study: PrEP program for men who have sex with men could lead to long-term cost savings

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

HIV prevention drug to be trialed by Britain's NHS

HIV prevention drug to be trialed by Britain's NHS

UTHealth participates in study to evaluate effectiveness of new injectable HIV medication

UTHealth participates in study to evaluate effectiveness of new injectable HIV medication

CDC guidelines for PrEP use to prevent HIV transmission do not go far enough, UCLA study suggests

CDC guidelines for PrEP use to prevent HIV transmission do not go far enough, UCLA study suggests

First large-scale clinical study of long-acting injectable HIV drug begins

First large-scale clinical study of long-acting injectable HIV drug begins

Added benefit of combination drug for HIV-infected patients not proven

Added benefit of combination drug for HIV-infected patients not proven

Researchers receive grant to test transcutaneously refillable implant that delivers HIV-prevention drugs

Researchers receive grant to test transcutaneously refillable implant that delivers HIV-prevention drugs

Topical delivery of AVR drug combination can provide complete protection against HIV

Topical delivery of AVR drug combination can provide complete protection against HIV

Nearly half of newly-infected HIV patients experience neurologic issues

Nearly half of newly-infected HIV patients experience neurologic issues

Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Genvoya approved as complete regimen for HIV treatment

Genvoya approved as complete regimen for HIV treatment

HIV prevention program undergoes “real world” evaluation

HIV prevention program undergoes “real world” evaluation

Young, single South African women adhere well to daily PrEP regimen to prevent HIV infection

Young, single South African women adhere well to daily PrEP regimen to prevent HIV infection